Bruker Co. (NASDAQ:BRKR) Stock Holdings Boosted by Montanaro Asset Management Ltd

Montanaro Asset Management Ltd grew its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 10.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 446,500 shares of the medical research company's stock after purchasing an additional 43,200 shares during the period. Bruker comprises approximately 5.5% of Montanaro Asset Management Ltd's investment portfolio, making the stock its 2nd largest position. Montanaro Asset Management Ltd owned 0.29% of Bruker worth $30,835,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Atria Investments Inc boosted its stake in shares of Bruker by 4.4% in the 3rd quarter. Atria Investments Inc now owns 12,698 shares of the medical research company's stock valued at $877,000 after purchasing an additional 538 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Bruker by 23.7% in the 3rd quarter. Assetmark Inc. now owns 1,729 shares of the medical research company's stock valued at $119,000 after purchasing an additional 331 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in Bruker during the 3rd quarter worth approximately $77,000. Kornitzer Capital Management Inc. KS acquired a new stake in Bruker during the 3rd quarter worth approximately $5,732,000. Finally, Malaga Cove Capital LLC boosted its position in Bruker by 42.9% during the 3rd quarter. Malaga Cove Capital LLC now owns 11,911 shares of the medical research company's stock worth $823,000 after buying an additional 3,576 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Trading Down 4.6 %

Shares of NASDAQ:BRKR traded down $2.76 during mid-day trading on Friday, hitting $57.73. The company had a trading volume of 1,077,386 shares, compared to its average volume of 1,454,654. The firm has a fifty day moving average price of $63.64 and a 200 day moving average price of $66.21. The company has a market capitalization of $8.74 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.83 and a beta of 1.20. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.75. Bruker Co. has a one year low of $54.55 and a one year high of $94.86.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same period in the previous year, the business posted $0.74 EPS. The business's revenue for the quarter was up 16.4% compared to the same quarter last year. As a group, research analysts forecast that Bruker Co. will post 2.39 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on BRKR shares. Wolfe Research downgraded shares of Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. Barclays cut their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a research report on Wednesday. Wells Fargo & Company cut their target price on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research report on Wednesday. Citigroup lowered their price target on shares of Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a report on Wednesday. Finally, TD Cowen lowered their price target on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $79.36.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.